首页 > 最新文献

Drug and alcohol review最新文献

英文 中文
Language Models for Standardising Clinical Notes and Information Extraction in Addiction Psychiatry-An Empirical Study. 成瘾精神病学临床记录规范化与信息提取的语言模型研究。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2026-01-01 Epub Date: 2025-10-29 DOI: 10.1111/dar.70059
Haritha Gireesh, Lekhansh Shukla, Prakrithi Shivaprakash, Animesh Mukherjee, Prabhat Chand, Pratima Murthy

Introduction: Electronic health records contain both structured and unstructured data, with unstructured clinical notes widely used in addiction psychiatry. Clinical notes have numerous errors and require proofreading to ensure accuracy and readability. This study evaluates natural language processing methods and adapts a Large Language Model (LLM) for proofreading clinical notes and extracting substance-related information.

Methods: We analysed clinical notes from a 5-year addiction medicine electronic health record dataset (2018-2023), selecting 6500 notes. The proofreading task involved correcting spelling and expanding abbreviations, while information extraction identified the presence of substance use and quantified the time since last use. Annotations by a team of doctors and nurses provided the gold standard. Against this, we compared the performance of existing solutions, including LLMs, and adapted an LLM for these tasks. The final model (fine-tuned LLAMA-3.2-3b) is also compared against a state-of-the-art commercial model (Generative Pretrained Transformer-4-o), and a human-preference experiment is done with masked raters choosing between model-generated and human-generated proofread versions.

Results: Proofreading improved readability and decreased out-of-vocabulary words. LLM-based solutions outperformed simpler approaches. The fine-tuned model outperformed the Generative Pretrained Transformer-4-o on both tasks. Masked human evaluators chose model-corrected clinical notes over the human-corrected version in 62% of trials (p < 0.001). On the information extraction task, while the overall performance is satisfactory (Mean F1 0.99), it is poor on rarer substance classes like hallucinogens.

Discussion and conclusions: Fine-tuned LLMs effectively standardised clinical notes and extracted structured information from addiction psychiatry records. Both these functionalities have important applications. Standardising improves the readability of clinical documentation and facilitates communication within and between interdisciplinary teams. Automated information extraction can decrease the burden on clinical staff, allow the creation of research cohorts from existing records and improve treatment outcomes by extracting critical information, such as 'time since last drink', which can be used to raise alerts. Even with limited computational resources, it is possible to adapt open-source LLMs for bespoke tasks in the field of addiction psychiatry. Our proposed solution is a model that can be deployed on consumer-grade servers, thus ensuring data privacy and security.

电子健康记录包含结构化和非结构化数据,非结构化临床记录广泛应用于成瘾精神病学。临床记录有许多错误,需要校对以确保准确性和可读性。本研究评估了自然语言处理方法,并采用大语言模型(LLM)来校对临床记录和提取物质相关信息。方法:我们分析了5年成瘾药物电子健康记录数据集中(2018-2023)的临床记录,选择了6500个记录。校对任务包括纠正拼写和扩展缩写,而信息提取识别物质使用的存在并量化自上次使用以来的时间。一组医生和护士的注释提供了黄金标准。与此相反,我们比较了现有解决方案的性能,包括LLM,并为这些任务调整了LLM。最后的模型(微调LLAMA-3.2-3b)也与最先进的商业模型(生成预训练变压器-4- 0)进行了比较,并在模型生成和人工生成的校对版本之间进行了屏蔽评分者的人类偏好实验。结果:校对提高了可读性,减少了词汇外的单词。基于llm的解决方案优于更简单的方法。在这两项任务上,微调模型都优于生成预训练的transformer -4- 0。在62%的试验中,蒙面的人类评估者选择了模型修正的临床记录,而不是人类修正的版本(p)。讨论和结论:微调的llm有效地标准化了临床记录,并从成瘾精神病学记录中提取了结构化信息。这两个功能都有重要的应用。标准化提高了临床文献的可读性,促进了跨学科团队内部和之间的沟通。自动信息提取可以减轻临床工作人员的负担,允许从现有记录中创建研究队列,并通过提取关键信息来改善治疗结果,例如“自上次饮酒以来的时间”,这些信息可用于发出警报。即使计算资源有限,也有可能将开源法学硕士用于成瘾精神病学领域的定制任务。我们提出的解决方案是一个可以部署在消费者级服务器上的模型,从而确保数据隐私和安全性。
{"title":"Language Models for Standardising Clinical Notes and Information Extraction in Addiction Psychiatry-An Empirical Study.","authors":"Haritha Gireesh, Lekhansh Shukla, Prakrithi Shivaprakash, Animesh Mukherjee, Prabhat Chand, Pratima Murthy","doi":"10.1111/dar.70059","DOIUrl":"10.1111/dar.70059","url":null,"abstract":"<p><strong>Introduction: </strong>Electronic health records contain both structured and unstructured data, with unstructured clinical notes widely used in addiction psychiatry. Clinical notes have numerous errors and require proofreading to ensure accuracy and readability. This study evaluates natural language processing methods and adapts a Large Language Model (LLM) for proofreading clinical notes and extracting substance-related information.</p><p><strong>Methods: </strong>We analysed clinical notes from a 5-year addiction medicine electronic health record dataset (2018-2023), selecting 6500 notes. The proofreading task involved correcting spelling and expanding abbreviations, while information extraction identified the presence of substance use and quantified the time since last use. Annotations by a team of doctors and nurses provided the gold standard. Against this, we compared the performance of existing solutions, including LLMs, and adapted an LLM for these tasks. The final model (fine-tuned LLAMA-3.2-3b) is also compared against a state-of-the-art commercial model (Generative Pretrained Transformer-4-o), and a human-preference experiment is done with masked raters choosing between model-generated and human-generated proofread versions.</p><p><strong>Results: </strong>Proofreading improved readability and decreased out-of-vocabulary words. LLM-based solutions outperformed simpler approaches. The fine-tuned model outperformed the Generative Pretrained Transformer-4-o on both tasks. Masked human evaluators chose model-corrected clinical notes over the human-corrected version in 62% of trials (p < 0.001). On the information extraction task, while the overall performance is satisfactory (Mean F1 0.99), it is poor on rarer substance classes like hallucinogens.</p><p><strong>Discussion and conclusions: </strong>Fine-tuned LLMs effectively standardised clinical notes and extracted structured information from addiction psychiatry records. Both these functionalities have important applications. Standardising improves the readability of clinical documentation and facilitates communication within and between interdisciplinary teams. Automated information extraction can decrease the burden on clinical staff, allow the creation of research cohorts from existing records and improve treatment outcomes by extracting critical information, such as 'time since last drink', which can be used to raise alerts. Even with limited computational resources, it is possible to adapt open-source LLMs for bespoke tasks in the field of addiction psychiatry. Our proposed solution is a model that can be deployed on consumer-grade servers, thus ensuring data privacy and security.</p>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":" ","pages":"e70059"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145387909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Self-Reported Willingness to Use Drugs in Public Health Research: Population-Level Projections of Adolescents' Decriminalised Cannabis Use and Associated Risk Profiles. 自我报告的药物使用意愿在公共卫生研究中的作用:青少年大麻非刑事化使用的人口水平预测和相关风险概况。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2026-01-01 Epub Date: 2025-10-26 DOI: 10.1111/dar.70061
Jasmina Burdzovic Andreas, Anne Line Bretteville-Jensen

Introduction: Public health planning in jurisdictions considering cannabis policy shifts may benefit from projections concerning post-policy changes in cannabis use and user profiles. Multiple scenarios concerning decriminalised cannabis use among Norwegian high school students were projected using a simple but under-utilised tool: their self-reported willingness to do so.

Methods: A nationally representative sample of Norwegian high school students (N = 3490) reported on their characteristics, cannabis use, and whether they would use cannabis if doing so were non-punishable. These estimates were scaled up to census data and used to project the population sizes of students who may initiate/increase decriminalised cannabis use under various hypothetical willingness-to-behaviour transition scenarios. Multinomial regression models were used to identify risk profiles associated with willingness to use decriminalised cannabis.

Results: One in five participants (20.3%) reported lifetime cannabis use, corresponding to 38,200 student users nationally. Among never-users, 8.0% reported willingness to initiate decriminalised cannabis use, while 22.3% were unsure. Among users, 40.3% reported willingness to increase decriminalised cannabis use, while 30.3% were unsure. Multiple projection scenarios indicated that both the prevalence (e.g., 12,000 new users nationally if all non-users willing to initiate use would do so) and frequency of cannabis use (e.g., 15,400 more frequent users nationally if all users willing to increase use would do so) would increase under decriminalisation, especially among youth with certain socio-demographic characteristics and recent histories of frequent use.

Discussion and conclusions: Asking young people about their intended cannabis use under different policies provides an easily understandable and highly relevant tool in public health research and planning.

导言:考虑大麻政策转变的司法管辖区的公共卫生规划可能受益于有关大麻使用和使用者概况的政策后变化的预测。使用一种简单但未充分利用的工具预测了挪威高中生使用大麻非刑事化的多种情况:他们自我报告的意愿。方法:挪威高中生的全国代表性样本(N = 3490)报告了他们的特征,大麻使用情况,以及如果这样做不会受到惩罚,他们是否会使用大麻。这些估计被扩大到人口普查数据,并用于预测在各种假设的意愿向行为过渡情景下可能开始/增加非刑事化大麻使用的学生的人口规模。使用多项回归模型来确定与使用非刑事化大麻意愿相关的风险概况。结果:五分之一的参与者(20.3%)报告终生使用大麻,相当于全国38,200名学生使用者。在从未使用过大麻的人群中,8.0%的人表示愿意开始使用大麻,而22.3%的人不确定。在使用者中,40.3%的人表示愿意增加大麻的非刑事化使用,而30.3%的人不确定。多种预测情景表明,在除罪化的情况下,使用大麻的流行程度(例如,如果所有非使用者都愿意开始使用大麻,全国将有12,000名新使用者)和频率(例如,如果所有使用者都愿意增加使用大麻,全国将有15,400名更频繁的使用者)都会增加,特别是在具有某些社会人口特征和最近经常使用大麻的青年中。讨论和结论:询问年轻人在不同政策下的大麻预期使用情况,为公共卫生研究和规划提供了一个易于理解和高度相关的工具。
{"title":"The Role of Self-Reported Willingness to Use Drugs in Public Health Research: Population-Level Projections of Adolescents' Decriminalised Cannabis Use and Associated Risk Profiles.","authors":"Jasmina Burdzovic Andreas, Anne Line Bretteville-Jensen","doi":"10.1111/dar.70061","DOIUrl":"10.1111/dar.70061","url":null,"abstract":"<p><strong>Introduction: </strong>Public health planning in jurisdictions considering cannabis policy shifts may benefit from projections concerning post-policy changes in cannabis use and user profiles. Multiple scenarios concerning decriminalised cannabis use among Norwegian high school students were projected using a simple but under-utilised tool: their self-reported willingness to do so.</p><p><strong>Methods: </strong>A nationally representative sample of Norwegian high school students (N = 3490) reported on their characteristics, cannabis use, and whether they would use cannabis if doing so were non-punishable. These estimates were scaled up to census data and used to project the population sizes of students who may initiate/increase decriminalised cannabis use under various hypothetical willingness-to-behaviour transition scenarios. Multinomial regression models were used to identify risk profiles associated with willingness to use decriminalised cannabis.</p><p><strong>Results: </strong>One in five participants (20.3%) reported lifetime cannabis use, corresponding to 38,200 student users nationally. Among never-users, 8.0% reported willingness to initiate decriminalised cannabis use, while 22.3% were unsure. Among users, 40.3% reported willingness to increase decriminalised cannabis use, while 30.3% were unsure. Multiple projection scenarios indicated that both the prevalence (e.g., 12,000 new users nationally if all non-users willing to initiate use would do so) and frequency of cannabis use (e.g., 15,400 more frequent users nationally if all users willing to increase use would do so) would increase under decriminalisation, especially among youth with certain socio-demographic characteristics and recent histories of frequent use.</p><p><strong>Discussion and conclusions: </strong>Asking young people about their intended cannabis use under different policies provides an easily understandable and highly relevant tool in public health research and planning.</p>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":" ","pages":"e70061"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145372406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Believing Alcohol Causes Cancer Moderate the Relationship Between Consumer Awareness of the Alcohol–Cancer Link and Support for Alcohol Policies? Findings From a Canadian Cross-Sectional Study 相信酒精导致癌症是否会缓和消费者对酒精与癌症联系的认识与对酒精政策的支持之间的关系?来自加拿大横断面研究的发现。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-07 DOI: 10.1111/dar.70072
Ashini Weerasinghe, Samantha M. Forbes, Erin Hobin

Introduction

Extending research observing an association between awareness that alcohol causes cancer and support for alcohol policies, this study examined if believing or accepting alcohol causes cancer moderates the relationship between awareness of alcohol as a carcinogen and policy support.

Methods

Adult alcohol consumers (n = 5180) in Canada completed an online survey in March–April 2023. Four separate logistic regression models were conducted with policy support affecting alcohol availability, pricing, marketing and labelling as outcomes to assess if believing alcohol causes seven types of cancer moderates the relationship between awareness of the alcohol–cancer link and support for alcohol policies. An interaction between awareness and belief was included as a predictor, adjusting for covariates.

Results

Overall, 29.3% were aware alcohol causes seven types of cancer and, of those aware, 83.6% believed this link. Those both aware of and believing that alcohol causes cancer had higher odds of supporting policies restricting alcohol availability (OR 1.76, 95% CI 1.13, 2.74) and marketing (OR 1.75, 95% CI 1.16, 2.64) than those not aware and did not believe. Consumers who were both aware of and believed the alcohol–cancer link had higher odds of supporting labelling policies (OR 1.59, 95% CI 1.05, 2.40), although this was not significant after adjusting for multiple comparisons.

Discussion and Conclusions

This study highlights that believing alcohol is a carcinogen moderates the relationship between awareness of the alcohol–cancer link and support for policies restricting alcohol availability and marketing. Future longitudinal studies are needed to test interventions for effectively raising awareness and strengthening belief and acceptance of alcohol-related cancer risks.

导言:本研究扩展了观察到酒精致癌意识与支持酒精政策之间关联的研究,考察了相信或接受酒精致癌是否会调节酒精作为致癌物的认识与政策支持之间的关系。方法:加拿大成年酒精消费者(n = 5180)于2023年3月至4月完成了一项在线调查。以影响酒精供应、定价、营销和标签的政策支持作为结果,进行了四个独立的逻辑回归模型,以评估相信酒精会导致七种癌症是否会调节对酒精与癌症之间联系的认识与对酒精政策的支持之间的关系。意识和信念之间的相互作用被包括作为预测因子,调整协变量。结果:总体而言,29.3%的人知道酒精会导致七种癌症,其中83.6%的人相信这一联系。那些知道并相信酒精导致癌症的人比那些不知道和不相信的人更有可能支持限制酒精供应的政策(OR 1.76, 95% CI 1.13, 2.74)和营销(OR 1.75, 95% CI 1.16, 2.64)。了解并相信酒精与癌症相关的消费者支持标签政策的几率更高(OR 1.59, 95% CI 1.05, 2.40),尽管在调整多重比较后这并不显著。讨论和结论:本研究强调,相信酒精是一种致癌物会缓和人们对酒精与癌症之间联系的认识和对限制酒精供应和营销政策的支持之间的关系。未来的纵向研究需要测试干预措施,以有效地提高认识,加强对酒精相关癌症风险的信念和接受。
{"title":"Does Believing Alcohol Causes Cancer Moderate the Relationship Between Consumer Awareness of the Alcohol–Cancer Link and Support for Alcohol Policies? Findings From a Canadian Cross-Sectional Study","authors":"Ashini Weerasinghe,&nbsp;Samantha M. Forbes,&nbsp;Erin Hobin","doi":"10.1111/dar.70072","DOIUrl":"10.1111/dar.70072","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Extending research observing an association between awareness that alcohol causes cancer and support for alcohol policies, this study examined if believing or accepting alcohol causes cancer moderates the relationship between awareness of alcohol as a carcinogen and policy support.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adult alcohol consumers (<i>n</i> = 5180) in Canada completed an online survey in March–April 2023. Four separate logistic regression models were conducted with policy support affecting alcohol availability, pricing, marketing and labelling as outcomes to assess if believing alcohol causes seven types of cancer moderates the relationship between awareness of the alcohol–cancer link and support for alcohol policies. An interaction between awareness and belief was included as a predictor, adjusting for covariates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 29.3% were aware alcohol causes seven types of cancer and, of those aware, 83.6% believed this link. Those both aware of and believing that alcohol causes cancer had higher odds of supporting policies restricting alcohol availability (OR 1.76, 95% CI 1.13, 2.74) and marketing (OR 1.75, 95% CI 1.16, 2.64) than those not aware and did not believe. Consumers who were both aware of and believed the alcohol–cancer link had higher odds of supporting labelling policies (OR 1.59, 95% CI 1.05, 2.40), although this was not significant after adjusting for multiple comparisons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>This study highlights that believing alcohol is a carcinogen moderates the relationship between awareness of the alcohol–cancer link and support for policies restricting alcohol availability and marketing. Future longitudinal studies are needed to test interventions for effectively raising awareness and strengthening belief and acceptance of alcohol-related cancer risks.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction—A Narrative Review 新型苯二氮卓类药物在澳大利亚的出现,证据,警报,临床管理和减少危害-叙述性回顾。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-07 DOI: 10.1111/dar.70086
Jack Freestone, Stassi Kypri, Jennifer L. Schumann, Erica Franklin, Cameron Francis, Monica J. Barratt, Amy Peacock, Rachel Sutherland, Brendan Clifford, Harriet MacDonald, Nadine Ezard, Kathryn Fletcher, Liam Acheson, Krista J. Siefried

Issues

In Australia, detections of novel benzodiazepines (NBZ) and related overdoses have increased markedly over the last five years. This review summarises Australian peer-reviewed literature and NBZ-related drug alerts, outlines the pharmacology of commonly detected NBZs and discusses approaches to harm reduction, managing toxicity, dependence and withdrawal.

Approach

Australian peer-reviewed articles published between January 2020 and June 2025 were identified via Embase, PubMed, Scopus and PsycINFO. Drug alerts from this period were retrieved from an Australian online repository. Data were extracted, coded and synthesised. Global literature on the pharmacology associated with commonly detected NBZs in Australia, was retrieved via Google Scholar as were sources on benzodiazepine-related harm reduction and clinical management and narratively summarised.

Key Findings

Between 2020 and 2025, NBZs were frequently detected from data from emergency department, forensic, drug checking and coronial sources. The most common were etizolam, clonazolam, clobromazolam, bromazolam, flualprazolam and flubromazolam. Twenty-three NBZ-related alerts were issued over this period, with nearly half of these (n = 11) issued between January and June of 2025. Health responses are hindered by limited pharmacological data, detection challenges and little research on the experiences of consumers.

Implications

To inform interventions spanning harm reduction and clinical management, future research must develop understandings of the pharmacology of NBZs and the experiences of people who source NBZs from unregulated markets.

Conclusion

NBZs were consistently detected across Australian coronial, toxicological, forensic and drug checking data sources from 2020 to 2025. Their emergence represents a public health concern, worthy of ongoing attention and response.

问题:在澳大利亚,新型苯二氮卓类药物(NBZ)和相关过量的检测在过去五年中显着增加。本综述总结了澳大利亚同行评审的文献和nbz相关的药物警报,概述了常见的nbz药理学,并讨论了减少危害、管理毒性、依赖和戒断的方法。方法:通过Embase、PubMed、Scopus和PsycINFO对2020年1月至2025年6月间发表的澳大利亚同行评议文章进行鉴定。从澳大利亚在线存储库检索了这一时期的药物警报。数据被提取、编码和合成。通过谷歌Scholar检索了与澳大利亚常见的NBZs相关的全球药理学文献,以及苯二氮卓类药物相关的减少危害和临床管理的来源,并进行了叙述性总结。主要发现:在2020年至2025年期间,经常从急诊科、法医、药物检查和冠状来源的数据中检测到nbz。最常见的是乙替唑仑、氯硝唑仑、氯丙唑仑、氯丙唑仑、氟丙唑仑和氟丙唑仑。在此期间发布了23个与nbz相关的警报,其中近一半(n = 11)是在2025年1月至6月发布的。有限的药理学数据、检测方面的挑战以及对消费者经验的研究很少,阻碍了卫生反应。启示:为了为减少危害和临床管理的干预提供信息,未来的研究必须发展对nbz药理学的理解,以及从不受监管的市场购买nbz的人的经历。结论:从2020年到2025年,在澳大利亚的冠状、毒理学、法医和药物检查数据源中持续检测到nbz。它们的出现是一个值得持续关注和应对的公共卫生问题。
{"title":"The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction—A Narrative Review","authors":"Jack Freestone,&nbsp;Stassi Kypri,&nbsp;Jennifer L. Schumann,&nbsp;Erica Franklin,&nbsp;Cameron Francis,&nbsp;Monica J. Barratt,&nbsp;Amy Peacock,&nbsp;Rachel Sutherland,&nbsp;Brendan Clifford,&nbsp;Harriet MacDonald,&nbsp;Nadine Ezard,&nbsp;Kathryn Fletcher,&nbsp;Liam Acheson,&nbsp;Krista J. Siefried","doi":"10.1111/dar.70086","DOIUrl":"10.1111/dar.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Issues</h3>\u0000 \u0000 <p>In Australia, detections of novel benzodiazepines (NBZ) and related overdoses have increased markedly over the last five years. This review summarises Australian peer-reviewed literature and NBZ-related drug alerts, outlines the pharmacology of commonly detected NBZs and discusses approaches to harm reduction, managing toxicity, dependence and withdrawal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Approach</h3>\u0000 \u0000 <p>Australian peer-reviewed articles published between January 2020 and June 2025 were identified via Embase, PubMed, Scopus and PsycINFO. Drug alerts from this period were retrieved from an Australian online repository. Data were extracted, coded and synthesised. Global literature on the pharmacology associated with commonly detected NBZs in Australia, was retrieved via Google Scholar as were sources on benzodiazepine-related harm reduction and clinical management and narratively summarised.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key Findings</h3>\u0000 \u0000 <p>Between 2020 and 2025, NBZs were frequently detected from data from emergency department, forensic, drug checking and coronial sources. The most common were etizolam, clonazolam, clobromazolam, bromazolam, flualprazolam and flubromazolam. Twenty-three NBZ-related alerts were issued over this period, with nearly half of these (<i>n</i> = 11) issued between January and June of 2025. Health responses are hindered by limited pharmacological data, detection challenges and little research on the experiences of consumers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Implications</h3>\u0000 \u0000 <p>To inform interventions spanning harm reduction and clinical management, future research must develop understandings of the pharmacology of NBZs and the experiences of people who source NBZs from unregulated markets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NBZs were consistently detected across Australian coronial, toxicological, forensic and drug checking data sources from 2020 to 2025. Their emergence represents a public health concern, worthy of ongoing attention and response.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Clinical Trials to Real-World Impact: Introducing a Computational Framework to Detect Endpoint Bias in Opioid Use Disorder Research 从临床试验到现实世界的影响:引入一个计算框架来检测阿片类药物使用障碍研究中的终点偏差。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-07 DOI: 10.1111/dar.70085
Gabriel J. Odom, Laura Brandt, Aaron Marker, Salvatore Giorgi, Ganesh Jainarain, H. Andrew Schwartz, Larry Au, Clinton Castro, The ENDPOINT Consortium

Introduction

Clinical trial endpoints are a ‘finite sequence of instructions to perform a task’ (measure treatment effectiveness), making them algorithms. Consequently, they may exhibit algorithmic bias: internal and external performance can vary across demographic groups, impacting fairness, validity and clinical decision-making.

Methods

We developed the open-source Detecting Algorithmic Bias (DAB) Pipeline in Python to identify endpoint ‘performance variance’—a specific algorithmic bias—as the proportion of minority participants changes. This pipeline assesses internal performance (on demographically matched test data) and external performance (on demographically diverse validation data) using metrics including F1 scores and area under the receiver operating characteristic curve (AUROC). We applied it to representative opioid use disorder (OUD) trial endpoints.

Results

F1 scores remained stable across minority representation levels, suggesting consistency in precision-recall balance (F1) despite demographic shifts. Conversely, AUROC measures were more sensitive, revealing significant performance variance. Training on demographically homogeneous populations boosted internal performance (accuracy within similar cohorts) but critically compromised external generalisability (accuracy within diverse cohorts). This pattern reveals an ‘endpoint bias trade-off’: optimising performance for homogeneous populations vs. having generalisable performance for the real world.

Discussion and Conclusions

Consistently performing endpoints for one demographic profile may lose generalisability during population shifts, potentially introducing endpoint bias. Increasing minority representation in the training data consistently improved generalisability. The endpoint bias trade-off reinforces the importance of diverse recruitment in OUD trials. The DAB Pipeline helps researchers systematically pinpoint when an endpoint may suffer ‘performance variance’ (i.e., bias). As an open-source tool, it promotes transparent endpoint evaluation and supports selecting demographically invariant OUD endpoints.

临床试验终点是“执行任务的有限指令序列”(衡量治疗有效性),使其成为算法。因此,他们可能会表现出算法偏差:内部和外部表现可能因人口统计学群体而异,影响公平性、有效性和临床决策。方法:我们在Python中开发了开源的检测算法偏差(DAB)管道,以识别端点“性能方差”-特定的算法偏差-随着少数参与者比例的变化。该管道使用包括F1分数和接受者工作特征曲线(AUROC)下面积在内的指标评估内部性能(人口统计学匹配的测试数据)和外部性能(人口统计学不同的验证数据)。我们将其应用于具有代表性的阿片类药物使用障碍(OUD)试验终点。结果:F1分数在少数族裔代表水平上保持稳定,这表明尽管人口结构发生了变化,但精确-召回平衡(F1)的一致性。相反,AUROC测量更敏感,显示出显著的表现差异。对人口统计学上同质人群的培训提高了内部表现(相似队列内的准确性),但严重损害了外部通用性(不同队列内的准确性)。这种模式揭示了一种“终点偏差权衡”:为同质人群优化性能vs.为现实世界提供一般化性能。讨论和结论:在人口变化过程中,始终如一地对一个人口统计概况执行终点可能会失去普遍性,从而可能引入终点偏倚。在训练数据中增加少数族裔的代表性持续提高了通用性。终点偏倚权衡强化了OUD试验中多样化招募的重要性。DAB Pipeline可以帮助研究人员系统地确定端点何时可能遭受“性能差异”(即偏差)。作为一个开源工具,它促进了透明的端点评估,并支持选择人口统计不变的OUD端点。
{"title":"From Clinical Trials to Real-World Impact: Introducing a Computational Framework to Detect Endpoint Bias in Opioid Use Disorder Research","authors":"Gabriel J. Odom,&nbsp;Laura Brandt,&nbsp;Aaron Marker,&nbsp;Salvatore Giorgi,&nbsp;Ganesh Jainarain,&nbsp;H. Andrew Schwartz,&nbsp;Larry Au,&nbsp;Clinton Castro,&nbsp;The ENDPOINT Consortium","doi":"10.1111/dar.70085","DOIUrl":"10.1111/dar.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Clinical trial endpoints are a ‘finite sequence of instructions to perform a task’ (measure treatment effectiveness), making them algorithms. Consequently, they may exhibit algorithmic bias: internal and external performance can vary across demographic groups, impacting fairness, validity and clinical decision-making.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We developed the open-source Detecting Algorithmic Bias (DAB) Pipeline in Python to identify endpoint ‘performance variance’—a specific algorithmic bias—as the proportion of minority participants changes. This pipeline assesses internal performance (on demographically matched test data) and external performance (on demographically diverse validation data) using metrics including F1 scores and area under the receiver operating characteristic curve (AUROC). We applied it to representative opioid use disorder (OUD) trial endpoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>F1 scores remained stable across minority representation levels, suggesting consistency in precision-recall balance (F1) despite demographic shifts. Conversely, AUROC measures were more sensitive, revealing significant performance variance. Training on demographically homogeneous populations boosted internal performance (accuracy within similar cohorts) but critically compromised external generalisability (accuracy within diverse cohorts). This pattern reveals an ‘endpoint bias trade-off’: optimising performance for homogeneous populations vs. having generalisable performance for the real world.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Consistently performing endpoints for one demographic profile may lose generalisability during population shifts, potentially introducing endpoint bias. Increasing minority representation in the training data consistently improved generalisability. The endpoint bias trade-off reinforces the importance of diverse recruitment in OUD trials. The DAB Pipeline helps researchers systematically pinpoint when an endpoint may suffer ‘performance variance’ (i.e., bias). As an open-source tool, it promotes transparent endpoint evaluation and supports selecting demographically invariant OUD endpoints.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Observational Study of Off-Premise Alcoholic Beverage Pricing Over Time in New South Wales, Australia 一项在澳大利亚新南威尔士州对非酒精饮料长期定价的观察性研究。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-07 DOI: 10.1111/dar.70077
Nicola Man, Mia Miller, Matthew Craig, Lexi Buckfield, Michael Livingston, Sarah Callinan, Heng Jiang, Isabella Britton, Alexandra Henderson, Michala Kowalski, Yan Yang, Qingyuan Linghu, Vandit Sadaphale, Wing See Yuen, Amy Peacock

Introduction

The price of alcohol is a key determinant of purchasing and consumption, yet few studies have assessed alcohol price in Australia. This study aimed to determine: (i) the comparative price of different alcohol product types; (ii) changes in price of alcoholic products over time inclusive of an excise duty indexation; and (iii) the proportion of alcoholic products under different price thresholds.

Methods

Data were collected monthly (July–October 2023) from five major off-premise alcohol retailer websites in three New South Wales locations with high alcohol-related mortality and morbidity (capital city, major city and remote location). Multilevel models estimated price differences and the proportion of products under three price thresholds, both by beverage type, subtype, location and over time.

Results

Wine in > 1 L vessels and high-strength cider were the cheapest products. The nominal price of alcohol for beer, spirits and premix increased in August–October compared with July 2023. Only wine fell under the $0.80 threshold, including 6% of all wine and 99.4% of wine in vessel size > 2 L. 14.3% of all wine and 14.6% of cider fell under A$1.30, and 26.4% of wine, 36.8% of cider, and 23.2% of beer fell under $1.80.

Discussion and Conclusions

Cheap alcohol products are predominantly those that attract ad valorem taxation. Beer, spirits and premixes increased in price likely due to indexation in August 2023, whereas wine and cider became comparatively cheaper over time. Ongoing monitoring of alcohol prices is needed to comprehensively evaluate market responses to alcohol pricing and other supply reduction policies.

引言:酒精的价格是购买和消费的关键决定因素,但很少有研究评估澳大利亚的酒精价格。本研究旨在确定:(i)不同类型酒精产品的比较价格;(二)含消费税指数化在内的酒类产品价格随时间的变化;(三)不同价格阈值下的酒类产品比例。方法:每月(2023年7月至10月)从新南威尔士州三个酒精相关死亡率和发病率高的地区(首府城市、主要城市和偏远地区)的五个主要非本地酒精零售商网站收集数据。多层模型估计了价格差异和三个价格阈值以下的产品比例,包括饮料类型、子类、位置和时间。结果:bbbb1l容器中的葡萄酒和高强度苹果酒是最便宜的产品。与2023年7月相比,8月至10月啤酒、烈酒和预混酒的名义价格有所上涨。只有葡萄酒低于0.80美元的门槛,包括6%的葡萄酒和99.4%的容器尺寸为bbbb20升的葡萄酒。14.3%的葡萄酒和14.6%的苹果酒价格低于1.30澳元,26.4%的葡萄酒、36.8%的苹果酒和23.2%的啤酒价格低于1.80澳元。讨论和结论:廉价酒产品主要是那些吸引从价税的产品。啤酒、烈酒和预混酒的价格上涨可能是由于2023年8月的指数化,而葡萄酒和苹果酒随着时间的推移变得相对便宜。需要持续监测酒精价格,以全面评估市场对酒精定价和其他减少供应政策的反应。
{"title":"An Observational Study of Off-Premise Alcoholic Beverage Pricing Over Time in New South Wales, Australia","authors":"Nicola Man,&nbsp;Mia Miller,&nbsp;Matthew Craig,&nbsp;Lexi Buckfield,&nbsp;Michael Livingston,&nbsp;Sarah Callinan,&nbsp;Heng Jiang,&nbsp;Isabella Britton,&nbsp;Alexandra Henderson,&nbsp;Michala Kowalski,&nbsp;Yan Yang,&nbsp;Qingyuan Linghu,&nbsp;Vandit Sadaphale,&nbsp;Wing See Yuen,&nbsp;Amy Peacock","doi":"10.1111/dar.70077","DOIUrl":"10.1111/dar.70077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The price of alcohol is a key determinant of purchasing and consumption, yet few studies have assessed alcohol price in Australia. This study aimed to determine: (i) the comparative price of different alcohol product types; (ii) changes in price of alcoholic products over time inclusive of an excise duty indexation; and (iii) the proportion of alcoholic products under different price thresholds.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were collected monthly (July–October 2023) from five major off-premise alcohol retailer websites in three New South Wales locations with high alcohol-related mortality and morbidity (capital city, major city and remote location). Multilevel models estimated price differences and the proportion of products under three price thresholds, both by beverage type, subtype, location and over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Wine in &gt; 1 L vessels and high-strength cider were the cheapest products. The nominal price of alcohol for beer, spirits and premix increased in August–October compared with July 2023. Only wine fell under the $0.80 threshold, including 6% of all wine and 99.4% of wine in vessel size &gt; 2 L. 14.3% of all wine and 14.6% of cider fell under A$1.30, and 26.4% of wine, 36.8% of cider, and 23.2% of beer fell under $1.80.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Cheap alcohol products are predominantly those that attract <i>ad valorem</i> taxation. Beer, spirits and premixes increased in price likely due to indexation in August 2023, whereas wine and cider became comparatively cheaper over time. Ongoing monitoring of alcohol prices is needed to comprehensively evaluate market responses to alcohol pricing and other supply reduction policies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-Induced Deaths and Non-Fatal Poisonings in Youth—Associations With Household Adversities and Out-Of-Home Care 青少年药物引起的死亡和非致命中毒——与家庭逆境和家庭外护理的关系。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-04 DOI: 10.1111/dar.70083
Karoliina Karjalainen, Kirsimarja Raitasalo, Sanna Rönkä

Introduction

Drug-induced deaths have increased in many countries, representing one of the most common causes of death among young people, including in Finland. More information is needed to understand the factors leading to these preventable incidents. We examined whether household adversities (parental substance use disorder (SUD), parental psychiatric disorder and long-term financial difficulties) and out-of-home care (OHC) were associated with drug-induced deaths or non-fatal poisonings.

Methods

Population-level data from Finnish national health care and social welfare registers was used. Two cohorts born in 1991 (n = 65,103) and 1997 (n = 58,998) were followed up from birth until the end of 2019. The outcome was drug-induced death/non-fatal drug poisoning. Mortality hazards were estimated using a competing events regression model.

Results

Youths experiencing household adversities (HR 1.60 for long-term income support) or OHC (HR 9.91) encountered a drug-induced death/non-fatal drug poisoning more often than others. Household adversities increased the hazard of drug-induced death/non-fatal poisoning, especially among those who had never been placed in OHC (HR 1.70 for parental SUD; 2.45 for long-term income support), whereas no statistically significant association was found among those who had experienced household adversities but had been placed in OHC.

Discussion and Conclusions

Household and other childhood adversities as well as substance use often form a complex and intertwined set of problems resulting in poor outcomes in young people's lives. Early, accessible and effective interventions are needed for families facing such challenges. Sufficient resources and needs-based services should be guaranteed to secure safe and healthy development for children with adverse childhood experiences.

导言:毒品导致的死亡在许多国家都有所增加,这是青年人死亡的最常见原因之一,包括在芬兰。需要更多的信息来了解导致这些可预防事件的因素。我们研究了家庭逆境(父母物质使用障碍(SUD)、父母精神障碍和长期经济困难)和家庭外护理(OHC)是否与药物引起的死亡或非致命性中毒有关。方法:采用芬兰国家卫生保健和社会福利登记处的人口水平数据。1991年(n = 65,103)和1997年(n = 58,998)出生的两个队列从出生到2019年底进行了随访。结果是药物性死亡/非致命性药物中毒。使用竞争事件回归模型估计死亡率风险。结果:经历家庭逆境(长期收入支持的HR为1.60)或OHC (HR为9.91)的青少年比其他人更常遇到药物引起的死亡/非致命性药物中毒。家庭逆境增加了药物引起的死亡/非致命性中毒的危险,特别是在那些从未被安置在OHC的人中(父母SUD的HR为1.70;长期收入支持的HR为2.45),而在经历过家庭逆境但被安置在OHC的人中没有发现统计学上显著的关联。讨论和结论:家庭和其他童年逆境以及药物使用往往形成一系列复杂和相互交织的问题,导致年轻人的生活结果不佳。面临这些挑战的家庭需要采取早期、可获得和有效的干预措施。应保证提供充足的资源和基于需求的服务,以确保有不良童年经历的儿童安全和健康地发展。
{"title":"Drug-Induced Deaths and Non-Fatal Poisonings in Youth—Associations With Household Adversities and Out-Of-Home Care","authors":"Karoliina Karjalainen,&nbsp;Kirsimarja Raitasalo,&nbsp;Sanna Rönkä","doi":"10.1111/dar.70083","DOIUrl":"10.1111/dar.70083","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Drug-induced deaths have increased in many countries, representing one of the most common causes of death among young people, including in Finland. More information is needed to understand the factors leading to these preventable incidents. We examined whether household adversities (parental substance use disorder (SUD), parental psychiatric disorder and long-term financial difficulties) and out-of-home care (OHC) were associated with drug-induced deaths or non-fatal poisonings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Population-level data from Finnish national health care and social welfare registers was used. Two cohorts born in 1991 (<i>n</i> = 65,103) and 1997 (<i>n</i> = 58,998) were followed up from birth until the end of 2019. The outcome was drug-induced death/non-fatal drug poisoning. Mortality hazards were estimated using a competing events regression model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Youths experiencing household adversities (HR 1.60 for long-term income support) or OHC (HR 9.91) encountered a drug-induced death/non-fatal drug poisoning more often than others. Household adversities increased the hazard of drug-induced death/non-fatal poisoning, especially among those who had never been placed in OHC (HR 1.70 for parental SUD; 2.45 for long-term income support), whereas no statistically significant association was found among those who had experienced household adversities but had been placed in OHC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Household and other childhood adversities as well as substance use often form a complex and intertwined set of problems resulting in poor outcomes in young people's lives. Early, accessible and effective interventions are needed for families facing such challenges. Sufficient resources and needs-based services should be guaranteed to secure safe and healthy development for children with adverse childhood experiences.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.70083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids 阿片类药物依赖者对阿片类药物激动剂治疗偏好的相关因素。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-04 DOI: 10.1111/dar.70079
M. J. Stowe, Anna Conway, Frederick L. Altice, Samantha College-Frisby, Phillip Read, Mark Montebello, Gilbert Whitton, Jeremy Hayllar, Mark Daglish, Victoria Cock, Michael Christmass, Sione Crawford, Charles Henderson, Gregory J. Dore, Chris Gough, Michael Farrell, Louisa Degenhardt, Jason Grebely

Introduction

Opioid agonist therapies (OAT) reduce adverse outcomes of illicit opioid use, with individual preferences potentially improving treatment outcomes. We explored preferences for OAT and associated factors in a national sample of people with opioid dependence.

Methods

This cross-sectional study recruited 400 participants (October 2020–April 2021) across Australia (excluding Tasmania) through snowball sampling. Participants completed an interviewer-administered questionnaire on sociodemographic and drug use characteristics. Multivariable logistic regression assessed factors associated with methadone preference (vs. buprenorphine).

Results

Among all participants (median age 45, 41% female, 87% ever received OAT), 92% (n = 366) indicated a preference for receiving OAT (vs. not receiving OAT) and 96% of those (n = 352) preferred a particular type of OAT. Among 366 with a stated preference, 61% (n = 216) preferred methadone and 39% (n = 136) preferred buprenorphine. Among those preferring buprenorphine (n = 136), 50% (n = 68) preferred buprenorphine ± naloxone and 50% (n = 68) preferred long-acting injectable buprenorphine. Independent correlates of preferring methadone included past month heroin use (aOR 1.78, 95% CI 1.06–3.00) and non-prescribed pharmaceutical opioid use (aOR 2.23, 95% CI 1.07, 4.95), and any prior receipt of methadone treatment (aOR 6.54, 95% CI 2.66, 17.91). Among those receiving OAT, a higher proportion of people currently receiving buprenorphine preferred their medication (61/66, 92%) compared to methadone recipients (180/235, 77%).

Discussion and Conclusions

Nearly all participants preferred OAT, mostly reflecting prior experiences, underscoring the need for expanded access to OAT in Australia. Given the multiple stated preferences, OAT options should include a variety of treatment options aligned with patient preferences, including expanded take-home options.

阿片类药物激动剂治疗(OAT)减少非法阿片类药物使用的不良后果,个人偏好可能改善治疗结果。我们在阿片类药物依赖人群的全国样本中探讨了对OAT的偏好及其相关因素。方法:本横断面研究通过滚雪球抽样在澳大利亚(不包括塔斯马尼亚州)招募了400名参与者(2020年10月至2021年4月)。参与者完成了一份由访谈者管理的关于社会人口学和药物使用特征的问卷。多变量logistic回归评估了与美沙酮偏好相关的因素(与丁丙诺啡相比)。结果:在所有参与者中(中位年龄45岁,41%女性,87%曾经接受过OAT), 92% (n = 366)表示倾向于接受OAT(相对于不接受OAT),其中96% (n = 352)倾向于特定类型的OAT。在366名有明确偏好的患者中,61% (n = 216)选择美沙酮,39% (n = 136)选择丁丙诺啡。选择丁丙诺啡(n = 136)的患者中,50% (n = 68)的患者选择丁丙诺啡±纳洛酮,50% (n = 68)的患者选择长效注射丁丙诺啡。偏好美沙酮的独立相关因素包括过去一个月的海洛因使用(aOR 1.78, 95% CI 1.06-3.00)和非处方阿片类药物使用(aOR 2.23, 95% CI 1.07, 4.95),以及之前接受过美沙酮治疗(aOR 6.54, 95% CI 2.66, 17.91)。在接受OAT治疗的患者中,目前接受丁丙诺啡治疗的患者(61/ 66,92%)比接受美沙酮治疗的患者(180/ 235,77%)更喜欢他们的药物。讨论和结论:几乎所有的参与者都倾向于OAT,主要反映了以前的经验,强调了在澳大利亚扩大OAT的必要性。鉴于多种陈述的偏好,OAT方案应包括与患者偏好一致的各种治疗方案,包括扩展的带回家方案。
{"title":"Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids","authors":"M. J. Stowe,&nbsp;Anna Conway,&nbsp;Frederick L. Altice,&nbsp;Samantha College-Frisby,&nbsp;Phillip Read,&nbsp;Mark Montebello,&nbsp;Gilbert Whitton,&nbsp;Jeremy Hayllar,&nbsp;Mark Daglish,&nbsp;Victoria Cock,&nbsp;Michael Christmass,&nbsp;Sione Crawford,&nbsp;Charles Henderson,&nbsp;Gregory J. Dore,&nbsp;Chris Gough,&nbsp;Michael Farrell,&nbsp;Louisa Degenhardt,&nbsp;Jason Grebely","doi":"10.1111/dar.70079","DOIUrl":"10.1111/dar.70079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Opioid agonist therapies (OAT) reduce adverse outcomes of illicit opioid use, with individual preferences potentially improving treatment outcomes. We explored preferences for OAT and associated factors in a national sample of people with opioid dependence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study recruited 400 participants (October 2020–April 2021) across Australia (excluding Tasmania) through snowball sampling. Participants completed an interviewer-administered questionnaire on sociodemographic and drug use characteristics. Multivariable logistic regression assessed factors associated with methadone preference (vs. buprenorphine).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among all participants (median age 45, 41% female, 87% ever received OAT), 92% (<i>n</i> = 366) indicated a preference for receiving OAT (vs. not receiving OAT) and 96% of those (<i>n</i> = 352) preferred a particular type of OAT. Among 366 with a stated preference, 61% (<i>n</i> = 216) preferred methadone and 39% (<i>n</i> = 136) preferred buprenorphine. Among those preferring buprenorphine (<i>n</i> = 136), 50% (<i>n</i> = 68) preferred buprenorphine ± naloxone and 50% (<i>n</i> = 68) preferred long-acting injectable buprenorphine. Independent correlates of preferring methadone included past month heroin use (aOR 1.78, 95% CI 1.06–3.00) and non-prescribed pharmaceutical opioid use (aOR 2.23, 95% CI 1.07, 4.95), and any prior receipt of methadone treatment (aOR 6.54, 95% CI 2.66, 17.91). Among those receiving OAT, a higher proportion of people currently receiving buprenorphine preferred their medication (61/66, 92%) compared to methadone recipients (180/235, 77%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Nearly all participants preferred OAT, mostly reflecting prior experiences, underscoring the need for expanded access to OAT in Australia. Given the multiple stated preferences, OAT options should include a variety of treatment options aligned with patient preferences, including expanded take-home options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Gender Differences in Injecting-Related Harms Among an Australian Sample of People Who Inject Drugs 了解澳大利亚注射吸毒者样本中注射相关危害的性别差异。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-04 DOI: 10.1111/dar.70067
Daisy Gibbs, Rachel Sutherland, Sarah Larney, Lucy Thi Tran, Amanda Roxburgh, Raimondo Bruno, Samantha Colledge-Frisby

Introduction

People who inject drugs may experience several non-viral injecting-related injuries and diseases (IRID), including skin and soft tissue infection (SSTI) and venous disease, often resulting from bacteria introduced via unsafe injecting practices or environments. Women are overrepresented among those reporting multiple and recent IRID. However, limited evidence exists about how gender interacts with known IRID risk factors.

Methods

Surveys were conducted 2009–2023 with approximately 900 Australians who inject drugs per year (N = 7538 total). Participants self-reported past-month drug use behaviours and IRID experience. We conducted multivariable binary logistic regression to determine the relationship between gender and SSTI and venous disease. To examine whether gender uniquely affected specific injecting risk behaviours with respect to SSTI and venous disease, two interaction terms were separately added: (i) gender and injecting frequency; (ii) gender and reuse of one's needles.

Results

Surveys were completed by 5038 men and 2500 women. Past-month SSTI was reported by 8% of the sample (95% confidence interval 7%–9%), with a higher proportion among women (10%) than men (7%). Overall, 4% reported past-month venous disease (95% confidence interval 3%–4%), a higher proportion among women (5%) than men (3%). Examining both outcomes, no statistically significant interactions between gender and needle reuse or injecting frequency were found.

Discussion and Conclusions

Despite no statistically significant interaction between gender and reuse or injecting frequency, our study demonstrates a gender difference in exposure to risk factors associated with SSTIs and venous disease. Interventions to reduce SSTI and venous disease, particularly those deemed safe and appropriate by women, are needed.

注射吸毒者可能会经历几种非病毒性注射相关损伤和疾病(IRID),包括皮肤和软组织感染(SSTI)和静脉疾病,通常是由不安全注射操作或环境引入的细菌引起的。在报告多次和最近的rid的人中,妇女的比例过高。然而,关于性别如何与已知的IRID风险因素相互作用的证据有限。方法:2009-2023年对每年约900名注射毒品的澳大利亚人(N = 7538)进行调查。参与者自我报告过去一个月的药物使用行为和IRID经历。我们采用多变量二元logistic回归来确定性别与SSTI和静脉疾病之间的关系。为了研究性别是否对性传播感染和静脉疾病的特定注射风险行为有独特影响,分别添加了两个相互作用项:(i)性别和注射频率;(ii)针头的性别和重复使用。结果:共有5038名男性和2500名女性完成了调查。8%的样本报告了过去一个月的SSTI(95%置信区间为7%-9%),其中女性的比例(10%)高于男性(7%)。总体而言,4%报告了过去一个月的静脉疾病(95%可信区间为3%-4%),女性(5%)的比例高于男性(3%)。检查这两个结果,没有发现性别与针头重复使用或注射频率之间有统计学意义的相互作用。讨论和结论:尽管性别与重复使用或注射频率之间没有统计学上显著的相互作用,但我们的研究表明,暴露于与性传播感染和静脉疾病相关的危险因素方面存在性别差异。需要采取干预措施,减少性传播感染和静脉疾病,特别是妇女认为安全和适当的干预措施。
{"title":"Understanding Gender Differences in Injecting-Related Harms Among an Australian Sample of People Who Inject Drugs","authors":"Daisy Gibbs,&nbsp;Rachel Sutherland,&nbsp;Sarah Larney,&nbsp;Lucy Thi Tran,&nbsp;Amanda Roxburgh,&nbsp;Raimondo Bruno,&nbsp;Samantha Colledge-Frisby","doi":"10.1111/dar.70067","DOIUrl":"10.1111/dar.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>People who inject drugs may experience several non-viral injecting-related injuries and diseases (IRID), including skin and soft tissue infection (SSTI) and venous disease, often resulting from bacteria introduced via unsafe injecting practices or environments. Women are overrepresented among those reporting multiple and recent IRID. However, limited evidence exists about how gender interacts with known IRID risk factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Surveys were conducted 2009–2023 with approximately 900 Australians who inject drugs per year (<i>N</i> = 7538 total). Participants self-reported past-month drug use behaviours and IRID experience. We conducted multivariable binary logistic regression to determine the relationship between gender and SSTI and venous disease. To examine whether gender uniquely affected specific injecting risk behaviours with respect to SSTI and venous disease, two interaction terms were separately added: (i) gender and injecting frequency; (ii) gender and reuse of one's needles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Surveys were completed by 5038 men and 2500 women. Past-month SSTI was reported by 8% of the sample (95% confidence interval 7%–9%), with a higher proportion among women (10%) than men (7%). Overall, 4% reported past-month venous disease (95% confidence interval 3%–4%), a higher proportion among women (5%) than men (3%). Examining both outcomes, no statistically significant interactions between gender and needle reuse or injecting frequency were found.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Despite no statistically significant interaction between gender and reuse or injecting frequency, our study demonstrates a gender difference in exposure to risk factors associated with SSTIs and venous disease. Interventions to reduce SSTI and venous disease, particularly those deemed safe and appropriate by women, are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery Capital in Chinese Drug Rehabilitation: Exploring Person-Centred and Community-Based Perspectives 中国戒毒所之康复资本:以人为本与以社区为基础之探讨。
IF 2.6 3区 医学 Q2 SUBSTANCE ABUSE Pub Date : 2025-12-03 DOI: 10.1111/dar.70088
Apei Song, George Christopher Dertadian, Jiaojiao He

Introduction

Chinese drug policy has begun to introduce recovery frameworks and rehabilitation models. These developments follow the recovery movement and align with several principles of recovery capital. However, this approach has tended to focus on what state systems understand recovery to be, often at the expense of how people experiencing drug dependence understand recovery. This study examines the different processes and purposes of recovery capital among those in drug rehabilitation programs in China, to highlight the importance of person-centred and community-based recovery.

Methods

From May to September 2024, the first author conducted semi-structured interviews with 24 people who had completed compulsory isolation rehabilitation in urban locations in China. Of these, 16 were undergoing community-based rehabilitation and eight had recently completed it. Thematic analysis was conducted to code for themes.

Results

Our study found that the legal and social stigma consequences of drug use impact how people access recovery resources in China. Data indicate that people's needs around employment, childcare and chronic illness management were often overlooked and that class differences played a significant role in access to recovery-related resources. Finally, participants provide a range of recommendations around making these resources more available and accessible, as well as practical strategies for navigating structural issues and barriers.

Discussion and Conclusions

Our findings confirm a significant mismatch between Chinese national rehabilitation policy frameworks and individual people's visions of recovery. Our study presents evidence for the benefit of reorienting recovery capital as an idea, and recovery policy in practice, around person-centred and community-based concerns.

导言:中国的毒品政策已经开始引入康复框架和康复模式。这些发展遵循复苏运动,并与复苏资本的若干原则相一致。然而,这种方法往往侧重于国家系统对康复的理解,往往以牺牲经历药物依赖的人对康复的理解为代价。本研究考察了中国戒毒项目中康复资本的不同过程和目的,以强调以人为本和以社区为基础的康复的重要性。方法:第一作者于2024年5月至9月对24名在中国城市地区完成强制隔离康复的人员进行半结构化访谈。其中16人正在接受社区康复,8人最近完成康复。进行主题分析,为主题编码。结果:我们的研究发现,中国吸毒的法律和社会耻辱后果影响了人们如何获得康复资源。数据表明,人们在就业、儿童保育和慢性病管理方面的需求往往被忽视,阶层差异在获得与康复有关的资源方面发挥了重要作用。最后,与会者就如何使这些资源更容易获得提出了一系列建议,并就解决结构性问题和障碍提出了切实可行的策略。讨论与结论:我们的研究结果证实了中国国家康复政策框架与个人康复愿景之间的显著不匹配。我们的研究提供了证据,证明将恢复资本重新定位为一种理念,并在实践中围绕以人为本和以社区为基础的问题重新定位恢复政策是有益的。
{"title":"Recovery Capital in Chinese Drug Rehabilitation: Exploring Person-Centred and Community-Based Perspectives","authors":"Apei Song,&nbsp;George Christopher Dertadian,&nbsp;Jiaojiao He","doi":"10.1111/dar.70088","DOIUrl":"10.1111/dar.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Chinese drug policy has begun to introduce recovery frameworks and rehabilitation models. These developments follow the recovery movement and align with several principles of recovery capital. However, this approach has tended to focus on what state systems understand recovery to be, often at the expense of how people experiencing drug dependence understand recovery. This study examines the different processes and purposes of recovery capital among those in drug rehabilitation programs in China, to highlight the importance of person-centred and community-based recovery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From May to September 2024, the first author conducted semi-structured interviews with 24 people who had completed compulsory isolation rehabilitation in urban locations in China. Of these, 16 were undergoing community-based rehabilitation and eight had recently completed it. Thematic analysis was conducted to code for themes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study found that the legal and social stigma consequences of drug use impact how people access recovery resources in China. Data indicate that people's needs around employment, childcare and chronic illness management were often overlooked and that class differences played a significant role in access to recovery-related resources. Finally, participants provide a range of recommendations around making these resources more available and accessible, as well as practical strategies for navigating structural issues and barriers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusions</h3>\u0000 \u0000 <p>Our findings confirm a significant mismatch between Chinese national rehabilitation policy frameworks and individual people's visions of recovery. Our study presents evidence for the benefit of reorienting recovery capital as an idea, and recovery policy in practice, around person-centred and community-based concerns.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"45 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug and alcohol review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1